Comprehensive clinical report from molecular diagnostics in cancer

Cancer is a genetic disease, as DNA is altered in each tumor. The changes differ greatly between different tumors and over time in a tumor. Many changes can occur in each tumor, and these changes may represent targets for therapy, or serve in other ways to inform on tumor management.

In order to facilitate and guide clinical interpretation of sequence changes identified from either gene panel, exome or whole genome sequencing, the Personal Cancer Genome Reporter was developed to:  i) systematically interrogate cancer genomes in the context of diagnostic, prognostic, and therapeutic biomarkers, ii) prioritize and highlight the most important findings, and iii) present the results in a format accessible to clinical experts. 

The workflow takes DNA sequence variation identified from sequencing (here single nucleotide variants (SNVs), or insertions or deletions (InDels), as well as copy number variant segments of DNA (CNA) as input, and outputs an annotated version using existing knowledge resources.

PCGR integrates a comprehensive set of knowledge resources related to tumor biology and therapeutic biomarkers, both at the gene and variant level.

The application generates a tiered report that will aid the interpretation of individual cancer genomes in a clinical setting, and it builds from publicly available resources to integrate knowledge in a structured way.   

The result is a structured report, here represented by an excerpt of a sample report: 




Oslo University Hospital - Intervention center




Clinical Decision Support

Sigve Nakken

Institute for Cancer Research

Send email

Eivind Hovig

Professor and Manager

OUS - Dept. of Tumor Biology and UiO - Dept. of informatics

+47 930 69 881

Send email

Relevant Projects

Regulatory frameworks and quality assurance for NGS-based diagnostics

Regulatory frameworks and quality assurance for NGS-based diagnostics

As patients, we trust that medical diagnostics are reliable and accurate, but how can clinical genomics labs ensure the quality of tests based on new technologies?